The table below shows Immunome Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$190.92M
-$110.79M
-$7.57M
-$28.69M
-$18.23M
-$12.13M
Capital expenditure
$9.69M
$7.17M
$831.00K
$248.00K
$79.00K
$586.00K
Investing cash flow
$60.80M
-$85.06M
-$30.48M
-$248.00K
-$79.00K
-$586.00K
Dividends paid
-
-
-
-
IMNM operating cash flow (10-K history)
Immunome Inc. reported operating cash flow of -$190.92M for fiscal year 2025. That is down 72.3% from -$110.79M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.60M (FY 2019) to -$190.92M. Figures come from the company's audited annual reports as filed with the SEC.